Improved T Cell Activation Bioassays for Development of Bispecific Antibodies and Engineered T Cell Immunotherapies
Immunotherapy aims to boost a patient’s own immune system to fight disease. In recent years, a variety of immunotherapy strategies aimed at inducing, strengthening or engineering T cell responses have emerged as promising approaches for the treatment of cancer and autoimmune disease.
Here we describe a platform of T cell activation bioassays for the development of CD3 bispecific antibodies and engineered T cell immunotherapies.
Specifically, we developed two bioluminescent reporter-based bioassays to measure T cell activation via CD3 (NFAT-RE) or CD3 + CD28 (IL-2 promoter). These
Here we describe a platform of T cell activation bioassays for the development of CD3 bispecific antibodies and engineered T cell immunotherapies.
Specifically, we developed two bioluminescent reporter-based bioassays to measure T cell activation via CD3 (NFAT-RE) or CD3 + CD28 (IL-2 promoter). These
